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The nitric oxide synthase (NOS) pathway has been clearly demonstrated to regulate angiogenesis. Increased levels of NO correlate
with tumour growth and spreading in different experimental and human cancers. Drugs interfering with the NOS pathway may be
useful in angiogenesis-dependent tumours. The aim of this study was to pharmacologically characterise certain ruthenium-based
compounds, namely NAMI-A, KP1339, and RuEDTA, as potential NO scavengers to be used as antiangiogenic/antitumour agents.
NAMI-A, KP1339 and RuEDTA were able to bind tightly and inactivate free NO in solution. Formation of ruthenium–NO adducts
was documented by electronic absorption, FT-IR spectroscopy and
1H-NMR. Pretreatment of rabbit aorta rings with NAMI-A,
KP1339 or RuEDTA reduced endothelium-dependent vasorelaxation elicited by acetylcholine. This effect was reversed by 8-Br-
cGMP. The key steps of angiogenesis, endothelial cell proliferation and migration stimulated by vascular endothelial growth factor
(VEGF) or NO donor drugs, were blocked by NAMI-A, KP1339 and RuEDTA, these compounds being devoid of any cytotoxic
activity. When tested in vivo, NAMI-A inhibited angiogenesis induced by VEGF. It is likely that the antitumour properties previously
observed for ruthenium-based NO scavengers, such as NAMI-A, are related to their NO-related antiangiogenic properties.
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Nitric oxide (NO) is an important signalling molecule that acts in
many tissues to regulate different physiological and pathological
processes. We demonstrated that NO stimulates angiogenesis and
mediates the effect of a number of angiogenic molecules (Ziche
et al, 1994, 1997; Parenti et al, 2001). In human tumours, NO plays
an important role in tumour growth and progression (Wink et al,
1998), as also evidenced by the increased expression of nitric oxide
synthase (NOS) found in a variety of tumours (Thomsen et al,
1994; Cobbs et al, 1995; Gallo et al, 1998; Klotz et al, 1998; Feng
et al, 2002). Nitric oxide has been shown to be important for
maintaining the vasodilator tone of tumours by regulating tumour
blood flow (Fukumura et al, 1997), and is an active mediator of
tumour angiogenesis (Gallo et al, 1998; Jadeski and Lala,
1999; Jadeski et al, 2000), intimately linked with cancer cell
growth and metastasis. Other mechanisms responsible for
stimulation of tumour progression and spreading by
tumour-derived NO are stimulation of tumour cell invasiveness
(Orucevic et al, 1999; Jadeski et al, 2000) as well as increased
expression of angiogenic factors (Morbidelli et al, 2001; Feng et al,
2002).
The availability of drugs able to specifically target NOS or
inactivate free NO in tumours can be regarded as a new alternative
therapeutic approach to inhibit tumour angiogenesis. Systemic
NOS inhibition through L-arginine derivatives in experimental
tumour models was demonstrated to be antitumoral, by reducing
tumour volume and increasing tumour necrosis (Thomsen et al,
1997; Jadeski and Lala, 1999; Swaroop et al, 2000). However, an
issue associated with NOS inhibitors is their lack of selectivity for
the three isoforms of NOS (Garvey et al, 1997; Cobb, 1999;
Cheshire, 2001). In the case of NO scavengers, the selectivity is
based on the rate of reaction with NO, which is dependent on the
concentration of NO and the scavenger. Ruthenium compounds,
designed as NO scavengers, work by rapidly and efficiently
reacting with NO (Bottomley, 1978; Fricker et al, 1997; Mosi et al,
2002, patent IPN: WO95/05814). These compounds have been
shown to exhibit pharmacological activity in vitro and in a number
of in vivo models for a variety of diseases including cancer (Clarke,
2002 and references therein). Furthermore, an angiogenesis
inhibitory activity has been reported for NAMI-A (imidazolium
trans-imidazole dimethylsulphoxide tetrachloro ruthenate,
ImH[trans-RuCl4(DMSO)Im) (Sanna et al, 2002; Vacca et al,
2002), a novel ruthenium(III)-based compound developed for
selectively treating solid tumour metastases (Sava and Bergamo,
1999).
The aim of the present study was to characterise the
pharmacological properties of representative ruthenium(III)
complexes on isolated aortic ring preparations and to test their
efficacy in inhibiting NO-dependent angiogenesis both in vitro
and in vivo. Specifically, we wanted to ascertain whether
the NO scavenging ability of these ruthenium(III) complexes and
the related interference with the angiogenic process might be
the basis of the biological properties of these innovative
metallodrugs.
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Drugs
NAMI-A was a gift of Professor E Alessio (Department of Chemical
Sciences, University of Trieste), KP1339 (sodium bis indazole
tetrachloro ruthenate, Na[trans-RuCl4Ind2]) was provided by
Professor B Keppler (Department of Inorganic Chemistry,
University of Vienna), and RuEDTA (K[Ru(HEDTA)Cl]) was
prepared according to the published procedure (Diamantis and
Dubrawsky, 1981). The identity and purity of the compounds was
checked by various analytical techniques including elemental
analysis, absorption and FT-IR spectroscopy. The chemical
features of these ruthenium(III) complexes are shown in Figure 1.
RuEDTA is a classical ruthenium(III) aminopolycarboxylate
complex whose chemical properties have been extensively
documented in previous studies (Matsubara and Creutz, 1979;
Diamantis and Dubrawsky, 1981); NAMI-A and KP1339 are mixed
ligand ruthenium(III) complexes (Alessio et al, 1993; Kratz et al,
1994). All are characterised by the presence of one or more labile
ligands that can be replaced by NO. All these ruthenium(III)
complexes are soluble in aqueous physiological buffers. RuEDTA
is sufficiently stable under physiological conditions except it
slowly dimerises (Bottomley, 1978). Both NAMI-A and KP1339,
when dissolved in water or in physiological buffers, progressively
hydrolyse and release the ruthenium(III) bound chlorides giving
rise to a number of hydrated and/or hydroxy ruthenium species, as
described (Mestroni et al, 1994; Kung et al, 2001).
Different NONOates were used as source of NO, mainly
MAHMA NONOate (Z-1-{N-methyl-N-[6-(N-methylammonio-
hexyl)amino]}diazen-1-ium-1,2-diolate, Alexis Biochemicals, Lau-
sen, Switzerland).
Acetylcholine hydrochloride, noradrenaline [( )arterenol hy-
drochloride], sodium nitroprusside (NaNP) and the cGMP stable
analogue, 8-Br-cGMP, were purchased from Sigma (St Louis, MO,
USA). Vascular endothelial growth factor (VEGF) was purchased
form Peprotech (Calbiochem, Milan, Italy).
NO-binding studies
Binding of NO to the individual ruthenium(III) complexes was
analysed by different spectroscopic techniques including visible
absorption, FT-IR and
1H-NMR. Visible spectrophotometric
studies were carried out on a Perkin-Elmer Lambda 20 BIO
instrument equipped with a thermostated cuvette. The hydrolysis
of ruthenium(III) complexes and the NO binding processes were
monitored continuously over 24h, acquiring spectra at 10min
intervals. The experiments were carried out in phosphate buffer
(NaH2PO4 50mM, NaCl 100mM, pH 7.4) at 251C, working at 100mM
ruthenium(III) concentrations. FT-IR spectra of similar samples
were recorded on a Perkin-Elmer Spectrum BXI instrument.
300MHz
1H-NMR spectra were measured on a Gemini 2000 Varian
Instrument. For
1H-NMR measurements, 1mM samples were
employed.
Aortic ring relaxation
The thoracic segment of the aorta was obtained from male New
Zealand rabbits and cut into rings of 3–4mm width (four to six
rings from each aorta). The preparations were suspended between
stainless-steel hooks and mounted in a 10ml organ bath filled with
warmed (371C) and oxygenated (95% O2,5 %C O 2) Krebs solution.
The incubation solution had the following composition (mM): NaCl
118, NaHCO3, 25, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5,
glucose 10. A tension of 2g was applied and isometric contraction
was recorded by a transducer on a polygraph chart (Battaglia
Rangoni). After 60–90min of equilibration, a concentration–
response curve for noradrenaline (NA, 0.1–1mM) was performed
and a concentration able to induce 50% of the maximum effect was
chosen. Following wash-out, the rings were preconstricted with
this concentration of NA and the cumulative relaxant effect of
acetylcholine (ACh, 0.1–10mM) was tested. The value of tension
developed following NA administration (1168768mg, n¼7) was
taken as 100% and the effect of ACh was referred to this value. The
vasorelaxant effect of ACh was tested 10min after the contractile
response to NA was fully developed. Experiments in which
10mM ACh induced a maximum relaxant effect of less than
40% were discarded. The preparation was then washed, and a
second concentration–relaxant effect curve for ACh was
obtained in the same preparation preconstricted by NA in the
presence of test compounds with or without 8-Br-cGMP (30min
exposure).
Cell lines and culture conditions
Coronary venular endothelial cells (CVEC) were isolated and
characterised as previously described (Morbidelli et al, 1996). Cells
were maintained in culture in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% bovine calf serum (CS) and
antibiotics (100Uml
 1 penicillin and 100mgml
 1 streptomycin)
on gelatin-coated dishes. Cells were cloned and each clone was
subcultured up to a maximum of 25 passages. Passages between 15
and 20 were used in these experiments.
Cytotoxicity
The cytotoxic effect of test substances was studied by trypan blue
exclusion. Briefly, endothelial cells were suspended in 0.1% CS
medium supplemented with increasing concentrations of the test
compounds and incubated at 371C for 4h. Cells were then counted
in a haemocytometer and the percentage of dead cells over the
total number of cells was calculated.
Migration assay
Cell migration was assessed in 48-well microchemotaxis chambers
(NeuroProbe, Biomap, Milan, Italy) on a polycarbonate filter (8mm
pore size). The filter was coated with type I collagen (100mgml
 1)
and bovine plasma fibronectin (10mgml
 1). A cell suspension
containing 12500 cells was added to the upper chamber of each
well. Test compounds were added to the cells in the upper
compartments, while angiogenic factors or NO donor drugs were
placed in the lower wells. After for 4h at 371C, cells that had
not migrated were removed and the filter was stained with
Diff-Quik (Biomap, Milan, Italy). Migrated cells were counted
in 10 random fields per well at a magnification of 400 (Ziche et al,
1997).
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Figure 1 Schematic representation of the chemical structure of NAMI-
A, KP1339 and RuEDTA as derived from crystallographic data. Notably, all
complexes are characterised by the presence of at least one labile ligand.
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Cell proliferation and survival were quantified by total cell number as
reported (Ziche et al, 1997). Briefly, 1.5 10
3 cells resuspended in
10% CS were seeded in each well of 96 multiwell plates. After
adherence (4h) the medium was replaced with 1% CS medium
containing test compounds in the absence or in the presence of the
angiogenic factors VEGF or the NO donor drug NaNP, and incubated
for 48h. The supernatants were removed from the multiwell plates
and the cells were fixed with methanol and stained with Diff-Quik.
Cell numbers were obtained by counting seven random fields at a
magnification of 100 with the aid of an ocular grid.
Rabbit corneal angiogenesis assay
Corneal assays were performed in New Zealand white rabbits
(Charles River, Calco, Como, Italy) in accordance with the
guidelines of the European Economic Community for animal care
and welfare (EEC Law No. 86/609). Briefly, after being anaesthetised
with sodium pentothal (30mgkg
 1), slow-release pellets bearing
test substances were implanted in micropockets surgically pro-
duced in the lower half of the cornea. Subsequent daily observation
of the implants was made with a slit-lamp stereomicroscope
without anaesthesia. An angiogenic response was scored positive
when budding of vessels from the limbal plexus occurred after 3–4
days and capillaries progressed to reach the implanted pellet. The
angiogenesis score was calculated (vessel density distance from
the limbus) as described (Ziche et al, 1997).
Statistical analysis
Results are expressed as mean values7s.e.m. Multiple compar-
isons were performed by one-way ANOVA and individual
differences tested by Fisher’s test after the demonstration of
significant intergroup differences by ANOVA.
RESULTS
Reaction of ruthenium(III) compounds with NO
Reactions of NAMI-A, KP1339 and RuEDTA with NO were carried
out in the reference phosphate buffer and analysed by absorption
and FT-IR spectroscopies and by
1H-NMR. MAHMA NONOate
was used as the source of NO. Notably, each MAHMA molecule
releases two NO equivalents. The molar ratio MAHMA/Ru(III)
used in this study was 2:1.
In the case of RuEDTA, NO bound quickly to the ruthenium(III)
centre blocking RuEDTA dimerisation, in agreement with previous
results by Fricker (Davies et al, 1997; Fricker, 1999; Fricker et al,
1997). The main product of the reaction was the diamagnetic
RuEDTA–NO adduct, characterised by an intense FT-IR band at
1880cm
 1.
FT-IR spectra for NO adducts of either NAMI-A or KP 1339 are
shown in Figure 2. Intense transitions, at 1850 and 1840cm
 1
respectively, were observed indicating formation of the [Ru–NO]
moiety. Independent NMR data showed that both paramagnetic
ruthenium(III) complexes upon reaction with NO rapidly trans-
formed into related diamagnetic species, formally containing the
{Ru
II NO
þ} moiety (data not shown). For all complexes, the
disappearance of the paramagnetic lines and the associated
formation of the NO adducts was complete within a few minutes.
Influence of NO scavengers on ACh-induced relaxation
in aortic rings
The pharmacological characterisation of the above compounds
was performed in rabbit aortic ring preparations bearing intact
endothelium.
Vessel preparations were incubated for 30min at 371C with
increasing concentrations of the compounds (0.1–3mM for NAMI-
A, 1–100mM for KP1339 and 1–100mM for RuEDTA) before
challenging with ACh. NAMI-A, KP1339 and RuEDTA were able to
interfere to a variable extent with ACh-induced vasorelaxation in a
concentration-dependent manner (Figure 3). The rank order of
potency was the following: NAMI-A4RuEDTA4KP1339 with
EC50s for 1mM ACh-induced relaxation of approximately 0.3, 1 and
10mM, respectively. The maximum effect caused by 10mM ACh was
reduced by about 90% in the presence of 3mM NAMI-A and by 80%
in the presence of 100mM RuEDTA. Not only the extent of
vasorelaxation was reduced by NO scavengers but also the time
required to obtain it. In the presence of NAMI-A, KP1339 and
RuEDTA, ACh-induced vasorelaxation was obtained within 60–90,
90–120 and 90–120s, respectively, vs 35–40s in the absence of
drugs.
We then tested whether the molecular mechanism of these NO
scavengers was because of inhibition of NO biosynthesis. Since
cyclic GMP (cGMP) and protein kinase G (PKG) are the
intracellular effectors of the vasodilatory effect of NO, we checked
whether the addition of 8-Br-cGMP, a stable cell-permeable
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Figure 2 FT-IR spectra of the reaction products of NAMI-A (A),
KP1339 (B) and RuEDTA (C) with NO. The intense band observed in the
1900–1800cm
-1 range is diagnostic of the presence of an Ru–NO moiety.
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sanalogue of cGMP, could revert the vasoconstrictive effect of these
NO scavengers. In the presence of 1mM NAMI-A, 3mM 8-Br-cGMP
was able to restore the vasodilatory effect of ACh by 66 % (data not
shown).
Effect of NO scavengers on endothelial cell migration
Microvascular endothelial cell migration and proliferation are key
events of the angiogenesis process. As previously demonstrated,
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Figure 3 Vasodilator responses of aortic ring preparations by increasing
concentrations of ACh. Noradrenaline (NA)-preconstricted rabbit aortic
rings were exposed to Krebs solution in the absence and in the presence of
increasing concentrations (0.1–3mM) of NAMI-A (A), (1–100mM)o f
KP1339 (B), and (1–100mM) of RuEDTA (C) before stimulation with ACh
(0.1–10mM). Vasodilatation is compared to ACh-induced responses. Data
are means7s.e.m. of five ring preparations. *Po0.05 vs basal.
25
50
75
100
125
150
M
i
g
r
a
t
i
o
n
 
(
n
u
m
b
e
r
 
o
f
 
c
e
l
l
s
 
c
o
u
n
t
e
d
 
p
e
r
 
w
e
l
l
)
Control
NAMI-A
25
50
75
100
125
150
Basal VEGF NaNP
Basal VEGF NaNP
Basal VEGF NaNP
M
i
g
r
a
t
i
o
n
 
(
n
u
m
b
e
r
 
o
f
 
c
e
l
l
s
 
c
o
u
n
t
e
d
 
p
e
r
 
w
e
l
l
)
Control
KP1339
25
50
75
150
125
100
M
i
g
r
a
t
i
o
n
 
(
n
u
m
b
e
r
 
o
f
 
c
e
l
l
s
 
c
o
u
n
t
e
d
 
p
e
r
 
w
e
l
l
)
Control
RuEDTA
*
*
*
*
*
*
*
*
A
B
C
Figure 4 Migration of postcapillary endothelial cells towards VEGF or
exogenous NO. Following incubation with NO scavengers (3mM NAMI-A,
3mM KP1339 or 30mM RuEDTA) endothelial cells were challenged towards
gradients of VEGF or NaNP in microchemotaxis Boyden chambers. After
4h, cell migration was measured by microscopic examination. Data
(means7s.e.m.) are reported as the number of cells counted per well
(n¼3 in triplicate). *Po0.05 vs control.
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effect of VEGF is mediated by the activation of endothelial-
constitutive NOS, NO production and cGMP accumulation
(Morbidelli et al, 1996; Ziche et al, 1997). Endothelial cells exposed
to NO scavengers were thus challenged toward a gradient of VEGF
(20ngml
 1) or NaNP (10mM). Cells pretreated with NAMI-A or
KP1339 (3mM each) or RuEDTA (30mM) showed reduced numbers
of migrating cells in the basal condition, and these compounds
were able to block completely the migratory effect elicited by VEGF
or NaNP (Figure 4). KP1339 was the least effective in reducing
NaNP-induced migration, in accordance with the pharmacological
data on ACh-induced vasorelaxation.
The inhibitory effect of metallodrugs was not because of
cytotoxicity, since no statistically relevant toxic effect was observed
in endothelial cell suspensions exposed to the NO scavengers for
4h at 371C (Table 1).
Effect of NO scavengers on endothelial cell proliferation
Endothelial cell proliferation is potently stimulated by either VEGF
or exogenous NO, the former acting through NOS and MAPK
pathway (Morbidelli et al, 1996; Parenti et al, 1998). As shown in
Figure 5(A–C), endothelial cell proliferation induced by VEGF
(20ngml
 1) or NaNP (10mM) was markedly inhibited by all NO
scavengers (3mM NAMI-A or KP1339 or 30mM RuEDTA). The
blockade of cell growth was accompanied by a change in their
morphology with the appearance of cytoplasmic vacuoles (data not
shown).
When cells were incubated with 3mM NAMI-A in the presence of
100mM 8-Br-cGMP, the proliferative effect of NaNP and VEGF was
restored (Figure 5D), demonstrating that the molecular mechan-
ism of NAMI-A in interfering with endothelial cell growth was the
blockade of soluble NO.
Effect of NO scavengers on in vivo angiogenesis
The antiangiogenic activity of NAMI-A observed in isolated cells
was also expressed in vivo in the avascular rabbit cornea against
the strong angiogenic response elicited by VEGF. Slow-release
pellets were prepared incorporating two different doses of NAMI-
A, namely 200 and 500ng, alone and in the presence of 200ng
VEGF. NAMI-A did not affect angiogenesis ‘per se’ and did not
Table 1 Lack of cytotoxic effect of NO scavengers on endothelial cells
Concentration (lM) NAMI-A KP1339 Ru-EDTA
06 736 736 73
11 5 756 71N D
31 3 748 71N D
10 15758 759 75
100 9711 1 711 2 73
Cytotoxicity of compounds was studied in endothelial cells by trypan blue exclusion
after 4h of incubation at 371C. Data (means7s.e.m.) are reported as the percentage
of dead cells over the total number of cells counted. ND¼not determined.
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Figure 5 Proliferation of postcapillary endothelial cells in the presence of VEGF or exogenous NO. (A–C) Cells were incubated in the absence and in
the presence of NO scavengers (3mM NAMI-A, 3mM KP1339 or 30mM RuEDTA). Cell proliferation was monitored after 48h incubation. Data
(means7s.e.m.) are reported as number of cells counted per well. (D) Cell proliferation in response to 10mM NaNP was studied in endothelial cells
exposed to 3mM NAMI-A in the presence of 100mM 8-Br-cGMP (n¼3 in triplicate). *Po0.05 vs control and
#Po0.05 vs NAMI-A alone.
Nitric oxide scavengers and angiogenesis
L Morbidelli et al
1488
British Journal of Cancer (2003) 88(9), 1484–1491 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sinduce any inflammatory response. The compound was able to
inhibit VEGF-induced response completely (Figure 6).
DISCUSSION
Ruthenium(III) complexes are an emerging family of metallodrugs
that are finding application as potential agents for the treatment of
cancer, septic shock, immune diseases and other pathological
conditions (Clarke et al, 1999). Among these agents, NAMI-A, a
compound found to be active against lung metastases (Sava and
Bergamo, 1999), tumour cell invasion (Zorzet et al, 2000), and
recently to possess antiangiogenesis properties (Pintus et al, 2002;
Sanna et al, 2002; Vacca et al, 2002) is presently undergoing
clinical trials as an antimetastatic agent.
Three representative ruthenium(III) complexes, namely NAMI-
A, KP1339 and RuEDTA were selected for further investigation in
an attempt to relate the NO scavenging properties to their activity
on the angiogenesis process. Unambiguous evidence for the
formation of tight ruthenium–nitrosyl adducts, and therefore
NO scavenging properties are here reported for NAMI-A and
KP1339. The properties of RuEDTA, previously reported (Davies
et al, 1997), have been confirmed.
Notably, these three complexes, upon reaction with NO, even at
stoichiometric ratios, exhibit a spectral behaviour that is
diagnostic of the formation of stable ruthenium–nitrosyl species,
that is the appearance of an intense IR transition at 1900–
1800cm
 1 and the disappearance of the hyperfine signals in the
1H-NMR spectra owing to loss of paramagnetism. In all cases the
reaction is complete within a few minutes.
The relaxation induced in rabbit isolated vessels by ACh, an
experimental paradigm originally employed for revealing the role
of NO in mediating blood vessel relaxation (Furchgott and
Zawadzki, 1980), is inhibited by all ruthenium complexes
examined, demonstrating their ability to interfere with NO binding
also in biological systems. NAMI-A is the most potent, whereas
KP1339 the weakest agent in antagonising the NO-mediated
effects. Reversal of the inhibition by 8-Br-cGMP, the intracellular
NO effector, clearly indicates that these complexes prevent NO
from exerting its action without affecting the intracellular
relaxation mechanism.
Endothelial cell functions linked to angiogenesis such as
migration and proliferation, typically stimulated by exogenous
NO donors (NaNP) or VEGF, the latter leading to sequential
activation of NOS and of the GMP-dependent kinase cascade
(Morbidelli et al, 1996; Ziche et al, 1997; Parenti et al, 1998), are
exquisitely sensitive to ruthenium complexes. All compounds
reduce, to a different extent, the migration of endothelial cells.
Similarly, the ruthenium complexes affect the stimulated pro-
liferation of endothelial cells measured at 48h, indicating
their long-lasting effects as NO scavengers. Since 8-Br-cGMP
counteracts the inhibition exerted by ruthenium compounds
on the proliferative effects elicited by NaNP or VEGF, it appears
that the action of these compounds is again exclusively confined
to the capture of nascent NO, without affecting the
intracellular mechanisms involved in proliferation. The absence
of cell toxicity further support the notion that these compounds,
at the concentrations examined, have no major intracellular
effects. The efficacy of NAMI-A as a NO scavenger, observed in
in vitro conditions driven by an increased availability of NO, is
confirmed in vivo in the rabbit cornea assay. The compound
exerts strong inhibition towards VEGF, whose angiogenic
response has been shown to be dependent on the activation
of the NOS pathway (Ziche et al, 1997; Ziche and Morbidelli,
2000).
The results of this study confirm recent findings on NAMI-A
demonstrating its inhibitory activity on proliferation, cell
migration and production of degradative enzymes (Vacca et al,
2002; Sanna et al, 2002). Also the antiangiogenic properties
previously observed in the chorioallantoic membrane (Vacca
et al, 2002) are confirmed in our in vivo assay in the rabbit
cornea.
The inhibition of angiogenesis exerted by NAMI-A has been
attributed to induction of apoptosis, which in turn is linked to
inhibition of the mitogen-activated protein kinase (MAPK)
signalling pathway and heat shock protein-27 downregulation
(Pintus et al, 2002; Sanna et al, 2002). Since MAPK is a
downstream effector of the NOS/cGMP pathway (Parenti et al,
1998), its inhibition by NAMI-A may be caused by the NO-binding
activity here reported. In support of this interpretation,
involving NO as a crucial signalling molecule, is the finding that
a cGMP stable analogue is able to revert the antiangiogenic effect
of NAMI-A.
In conclusion, this study demonstrates that ruthenium(III)
compounds inhibit NO-dependent angiogenesis, and highlights a
rather innovative mechanism of action for heavy metal-based
compounds, which are currently hypothesised to act via DNA-
binding (Malina et al, 2001). The antimetastatic activity of these
metallodrugs might be multiple, interfering with the endothelial
cell functions during angiogenesis, angiogenic factor overexpres-
sion, the vasodilating state of tumours and probably tumour cell
invasiveness, each event being demonstrated by different groups as
NO-dependent (Fukumura et al, 1997; Gallo et al, 1998; Jadeski
and Lala, 1999; Orucevic et al, 1999; Jadeski et al, 2000; Morbidelli
et al, 2001; Feng et al, 2002). On the speculative side, it may be
suggested that tumours producing high NO levels and exhibiting a
high angiogenic output would be more sensitive to ruthenium(III)-
based drugs.
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Figure 6 Effect of NAMI-A on in vivo angiogenesis in the rabbit corneal
model. Pellets bearing NAMI-A and/or VEGF165 were prepared and
surgically implanted in the corneal stroma of albino rabbits. The angiogenic
response of NAMI-A was tested per se (A) and in the presence of VEGF
(B). Data are reported as angiogenic score during time (days). Numbers
are means of at least three implants per experimental point.
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